vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and SAUL CENTERS, INC. (BFS). Click either name above to swap in a different company.

SAUL CENTERS, INC. is the larger business by last-quarter revenue ($75.1M vs $45.1M, roughly 1.7× Amarin Corp plc). SAUL CENTERS, INC. runs the higher net margin — 8.7% vs -23.3%, a 31.9% gap on every dollar of revenue. On growth, SAUL CENTERS, INC. posted the faster year-over-year revenue change (10.6% vs 7.0%). Over the past eight quarters, SAUL CENTERS, INC.'s revenue compounded faster (6.2% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.

AMRN vs BFS — Head-to-Head

Bigger by revenue
BFS
BFS
1.7× larger
BFS
$75.1M
$45.1M
AMRN
Growing faster (revenue YoY)
BFS
BFS
+3.6% gap
BFS
10.6%
7.0%
AMRN
Higher net margin
BFS
BFS
31.9% more per $
BFS
8.7%
-23.3%
AMRN
Faster 2-yr revenue CAGR
BFS
BFS
Annualised
BFS
6.2%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
BFS
BFS
Revenue
$45.1M
$75.1M
Net Profit
$-10.5M
$6.5M
Gross Margin
Operating Margin
35.5%
65.4%
Net Margin
-23.3%
8.7%
Revenue YoY
7.0%
10.6%
Net Profit YoY
33.0%
-19.6%
EPS (diluted)
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
BFS
BFS
Q1 26
$45.1M
Q4 25
$49.2M
$75.1M
Q3 25
$49.7M
$72.0M
Q2 25
$72.7M
$70.8M
Q1 25
$42.0M
$71.9M
Q4 24
$62.3M
$67.9M
Q3 24
$42.3M
$67.3M
Q2 24
$67.5M
$66.9M
Net Profit
AMRN
AMRN
BFS
BFS
Q1 26
$-10.5M
Q4 25
$-1.2M
$6.5M
Q3 25
$-7.7M
$10.5M
Q2 25
$-14.1M
$10.7M
Q1 25
$-15.7M
$9.8M
Q4 24
$-48.6M
$8.1M
Q3 24
$-25.1M
$14.5M
Q2 24
$1.5M
$14.4M
Gross Margin
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
73.6%
Q2 24
63.4%
74.2%
Operating Margin
AMRN
AMRN
BFS
BFS
Q1 26
35.5%
Q4 25
-12.9%
65.4%
Q3 25
-22.4%
69.1%
Q2 25
-22.0%
68.7%
Q1 25
-39.9%
66.5%
Q4 24
-84.3%
82.9%
Q3 24
-59.5%
72.8%
Q2 24
-0.8%
75.0%
Net Margin
AMRN
AMRN
BFS
BFS
Q1 26
-23.3%
Q4 25
-2.5%
8.7%
Q3 25
-15.6%
14.6%
Q2 25
-19.4%
15.1%
Q1 25
-37.4%
13.6%
Q4 24
-78.0%
11.9%
Q3 24
-59.4%
21.5%
Q2 24
2.3%
21.6%
EPS (diluted)
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
$0.00
$0.15
Q3 25
$-0.02
$0.32
Q2 25
$-0.03
$0.33
Q1 25
$-0.04
$0.29
Q4 24
$-0.12
$0.22
Q3 24
$-0.06
$0.48
Q2 24
$0.00
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
BFS
BFS
Cash + ST InvestmentsLiquidity on hand
$307.8M
$8.7M
Total DebtLower is stronger
$468.4M
Stockholders' EquityBook value
$307.8M
Total Assets
$645.8M
$2.2B
Debt / EquityLower = less leverage
1.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
BFS
BFS
Q1 26
$307.8M
Q4 25
$302.6M
$8.7M
Q3 25
$286.6M
$11.8M
Q2 25
$298.7M
$5.3M
Q1 25
$281.8M
$6.5M
Q4 24
$294.2M
$10.3M
Q3 24
$305.7M
$7.2M
Q2 24
$306.7M
$6.9M
Total Debt
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
$468.4M
Q3 25
$1.6B
Q2 25
$1.6B
Q1 25
$1.5B
Q4 24
$455.8M
Q3 24
$1.5B
Q2 24
$1.4B
Stockholders' Equity
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
$459.3M
$307.8M
Q3 25
$458.9M
$316.6M
Q2 25
$464.9M
$322.4M
Q1 25
$473.7M
$328.4M
Q4 24
$486.2M
$335.8M
Q3 24
$531.4M
$341.8M
Q2 24
$551.9M
$345.7M
Total Assets
AMRN
AMRN
BFS
BFS
Q1 26
$645.8M
Q4 25
$670.8M
$2.2B
Q3 25
$659.8M
$2.2B
Q2 25
$670.1M
$2.1B
Q1 25
$655.7M
$2.1B
Q4 24
$685.3M
$2.1B
Q3 24
$750.6M
$2.1B
Q2 24
$799.9M
$2.1B
Debt / Equity
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
1.52×
Q3 25
5.02×
Q2 25
4.85×
Q1 25
4.70×
Q4 24
1.36×
Q3 24
4.37×
Q2 24
4.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
BFS
BFS
Operating Cash FlowLast quarter
$99.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
15.35×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
$15.3M
$99.8M
Q3 25
$-12.7M
$20.6M
Q2 25
$16.6M
$26.6M
Q1 25
$-12.5M
$30.4M
Q4 24
$-13.3M
$121.2M
Q3 24
$-2.4M
$26.5M
Q2 24
$-2.7M
$32.1M
Free Cash Flow
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$-28.3M
Q2 24
$-12.5M
FCF Margin
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-42.1%
Q2 24
-18.7%
Capex Intensity
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
81.5%
Q2 24
66.7%
Cash Conversion
AMRN
AMRN
BFS
BFS
Q1 26
Q4 25
15.35×
Q3 25
1.97×
Q2 25
2.48×
Q1 25
3.10×
Q4 24
14.98×
Q3 24
1.83×
Q2 24
-1.81×
2.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

BFS
BFS

Segment breakdown not available.

Related Comparisons